Skip to main content
. 2012 Jan 26;9:33. doi: 10.1186/1743-422X-9-33

Table 1.

Calculated IC50 and IC90 for λ-carrageenan, cellulose sulfate, and dextran sulfate (mg/mL)

P4-R5 MAGI Human PBMCs

HIV-1 BaL HIV-1 IIIB HIV-1 BaL HIV-1 IIIB

IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
LC 0.0037 (± 0.0009) 6.04a (± 0.79) 0.064 (± 0.0084) 1.96 (± 0.077) 0.967 (± 0.53) 3.16b (± 0.04) 0.061 (± 0.021) 0.87 (± 0.32)

CS 0.023 (± 0.0018) 1.24 (± 0.47) 0.003 (± 0.00047) 0.026 (± 0.00073) 0.0026 (± 0.0003) 0.0091 (± 0.0052) 0.014 (± 0.0034) 0.03 (± 0.0025)

DS 0.0058 (± 0.0011) 0.031 (± 0.012) 0.00052 (± 0.00011) 0.0028 (± 0.00015) 0.14 (± 0.045) 0.9 (± 0.18) 0.00056 (± 0.00017) 0.014 (± 0.0064)

CS cellulose sulfate, DS dextran sulfate, IC50 the concentration at which 50% virus inhibition is achieved, IC90 the concentration at which 90% virus inhibition is achieved, LC λ-carrageenan, PBMCs peripheral blood mononuclear cells

aExtrapolated concentration

bLC concentrations > 3.16 mg/mL could not be used due to excessive solution viscosity. Because 90% inhibition of HIV-1 BaL infection by LC in PBMCs was not achieved, the LC IC75 (concentration that resulted in a 75% reduction of infection with respect to mock-treated, HIV-1-infected cells) was calculated and used in the PBMC washout experiments

Presented data are from two independent experiments in which each data point was examined in triplicate